Englumafusp alfa联合glofitamab治疗B细胞非霍奇金淋巴瘤的1期试验
本研究为开放标签、非随机1期试验的第2部分,评估CD19-4-1BBL共刺激分子englumafusp alfa联合glofitamab在复发或难治性B细胞非霍奇金淋巴瘤患者中的剂量递增。共入组134例患者,未达到最大耐受剂量,在C2D8给药的侵袭性B-NHL亚组中总缓解率和完全代谢缓解率分别为68.7%和56.6%,安全性特征与glofitamab单药一致。
要点
- Englumafusp alfa联合glofitamab在复发/难治B-NHL中显示出鼓舞人心的疗效。
- 未达到最大耐受剂量,安全性特征与glofitamab单药一致。
- 侵袭性B-NHL亚组(C2D8,n=83)总缓解率68.7%,完全代谢缓解率56.6%。
核心结论
- Englumafusp alfa联合glofitamab在复发或难治性B-NHL患者中与鼓舞人心的疗效和稳健的药效学调节相关,安全性特征与glofitamab单药一致。
研究设计与样本
- 开放标签、非随机1期研究第2部分,评估englumafusp alfa剂量递增联合glofitamab。
- 共入组134例患者,包括109例侵袭性B-NHL和25例惰性B-NHL。
- Obinutuzumab预处理在首次glofitamab剂量前7天给药;第1周期glofitamab阶梯剂量后,进行11个周期glofitamab联合englumafusp alfa治疗。
- Englumafusp alfa初始剂量在第2周期第8天(C2D8)或第1周期第10天(C1D10)给药。
- 主要目标为确定最大耐受剂量以及安全性和耐受性。
主要发现
- 未达到englumafusp alfa的最大耐受剂量;发生1例剂量限制性毒性(5级耶氏肺孢子菌肺炎)。
- 98.5%的患者报告不良事件,59.0%发生3/4级不良事件,10例患者发生5级不良事件。
- 在C2D8给药的侵袭性B-NHL亚组(n=83)中,总缓解率和完全代谢缓解率分别为68.7%和56.6%。
- 在无既往嵌合抗原受体T细胞治疗暴露的患者(n=41)中,相应缓解率分别为73.2%和65.9%。
- Englumafusp alfa给药后的药效学变化支持其共刺激作用模式。
临床怎么用
- 对于复发或难治性B-NHL,englumafusp alfa联合glofitamab可能是一种有效的现成治疗方案。
- 联合方案的安全性特征与glofitamab单药一致,支持进一步临床开发。
局限性
- 本研究为开放标签、非随机1期试验,样本量有限。
- 未达到最大耐受剂量,需进一步确定推荐2期剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is an unmet need for effective, off-the-shelf therapies for relapsed or refractory aggressive B cell non-Hodgkin lymphoma (B-NHL). Part 2 of the current study was an open-label, nonrandomized, phase 1 study of escalating doses of the CD19-4-1BBL co-stimulatory molecule, englumafusp alfa, in combination with glofitamab in patients with relapsed or refractory B-NHL. Obinutuzumab pretreatment was administered 7 days before the first glofitamab dose. Glofitamab step-up dosing in cycle 1 was followed by 11 cycles of glofitamab plus englumafusp alfa. Englumafusp alfa was administered at escalating doses, with the initial dose on cycle 2 day 8 (C2D8) or cycle 1 day 10 (C1D10). Primary objectives were to establish the maximum tolerated dose, and safety and tolerability. A total of 134 patients were enrolled, including 109 with aggressive B-NHL and 25 with indolent B-NHL. The maximum tolerated dose of englumafusp alfa was not reached; one dose-limiting toxicity occurred (grade 5 Pneumocystis jirovecii pneumonia). Adverse events were reported in 98.5% of all patients, with grade 3/4 adverse events in 59.0%. Grade 5 adverse events occurred in ten patients. In the subgroup of C2D8 patients with aggressive B-NHL (n = 83), overall response and complete metabolic response rates were 68.7% and 56.6%, respectively; among those without previous exposure to chimeric antigen receptor T cell therapy (n = 41), the corresponding rates were 73.2% and 65.9%. Pharmacodynamic changes following englumafusp alfa administration supported its co-stimulatory mode of action. These data demonstrate that the addition of englumafusp alfa to glofitamab is associated with encouraging efficacy and robust pharmacodynamic modulation, as well as a safety profile consistent with glofitamab monotherapy, in patients with relapsed or refractory B-NHL. CTIS identifier: 2022-502616-37-00 ; ClinicalTrials.gov identifier: NCT04077723 .
引用
- Hutchings M, Dickinson M, Gritti G, et al. Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial. Nat Med. 2026. PMID: 42463852. doi:10.1038/s41591-026-04533-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。